http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109652454-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99c8a63122bb30e25468fd4e91027fcd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0694 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate | 2018-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72645d0569fbfdb0f0dbef043607525a |
| publicationDate | 2019-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109652454-A |
| titleOfInvention | A kind of drug rapid screening method based on gp120/CCR5 block function and its biological effect |
| abstract | The present invention establishes a kind of drug rapid screening method based on gp120/CCR5 block function and its biological effect: red fluorescent protein tagRFP is coupled to gp120 protein carboxyl groups end (C-terminal), carrier for expression of eukaryon is constructed, and prepares gp120-tagRFP fusion protein；By the building of source of people CD4 protein gene under CMV promoter；Source of people CCR5 is gene constructed in CMV promoter downstream, and by green fluorescence protein gene d2EGFP building in the downstream of the artificial compound controlling element of NF- κ B RE-TATA-like, the two is implemented in the same slow virus carrier；And it establishes and novel surely turns cell line CD4.CCR5.CCR5.NF- κ BR-d2EGFP/Jurkat；Blocking agent is screened with the affine carry out fluorescence detection of gp120-tagRFP and cell line.This method can accurately reflect the effect of anti-CCR5 medicine, and can obtain block function and CC chemotactic factor (CF)/CCR5 signal path biological effect data simultaneously, construct the experimental model for quickly screening anti-CCR5 drug and assessing its biological effect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110922483-A |
| priorityDate | 2018-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 448.